Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases.

IF 4.9 Q1 CHEMISTRY, MEDICINAL
ACS Pharmacology and Translational Science Pub Date : 2024-10-19 eCollection Date: 2024-11-08 DOI:10.1021/acsptsci.4c00405
Eleni Sflakidou, Bikash Adhikari, Christos Siokatas, Elmar Wolf, Vasiliki Sarli
{"title":"Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases.","authors":"Eleni Sflakidou, Bikash Adhikari, Christos Siokatas, Elmar Wolf, Vasiliki Sarli","doi":"10.1021/acsptsci.4c00405","DOIUrl":null,"url":null,"abstract":"<p><p>Monopolar spindle 1 (Mps1, also known as TTK) and Aurora kinase (AURK) A and B are critical regulators of mitosis and have been linked to the progression of various cancers. Here, we report the design, synthesis, and biological evaluation of a series of PROTACs (proteolysis-targeting chimeras) targeting TTK and AURKs. We synthesized various degrader molecules based on four different 2-aminoadenine-based ligands, recruiting either cereblon or VHL as the E3-ligase. Our research showed that the nature of the linker and modification of the ligand significantly influence the target specificity and degradation efficacy. Notably, compound <b>19</b>, among the most potent degraders, demonstrated robust proteasome-mediated degradation of TTK with <i>D</i> <sub>max</sub> of 66.5% and DC<sub>50</sub> value (6 h) of 17.7 nM as compared to its structurally akin inhibitor control, <b>23</b>. The cytotoxicity of most of the synthesized chimeras against acute myeloid leukemia cell line MV4-11 was lower than that of the corresponding parent inhibitors. However, we could also identify degraders such as <b>15</b> and <b>26</b> that induce potent AURKA degradation and display comparable antiproliferative activities to their parent compound <b>SF1</b>. Compound <b>15</b> degrades AURKA with low DC<sub>50</sub> value of 2.05 nM, which is 77-fold and 21-fold more selective toward AURKB and TTK and has an EC<sub>50</sub> value of 39 nM against cancer MV4-11 cells. Overall, the observations we made with the degrader molecules we developed can further aid in the design and development of optimized TTK or AURK degraders for cancer therapy.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 11","pages":"3488-3501"},"PeriodicalIF":4.9000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555526/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/acsptsci.4c00405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/8 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Monopolar spindle 1 (Mps1, also known as TTK) and Aurora kinase (AURK) A and B are critical regulators of mitosis and have been linked to the progression of various cancers. Here, we report the design, synthesis, and biological evaluation of a series of PROTACs (proteolysis-targeting chimeras) targeting TTK and AURKs. We synthesized various degrader molecules based on four different 2-aminoadenine-based ligands, recruiting either cereblon or VHL as the E3-ligase. Our research showed that the nature of the linker and modification of the ligand significantly influence the target specificity and degradation efficacy. Notably, compound 19, among the most potent degraders, demonstrated robust proteasome-mediated degradation of TTK with D max of 66.5% and DC50 value (6 h) of 17.7 nM as compared to its structurally akin inhibitor control, 23. The cytotoxicity of most of the synthesized chimeras against acute myeloid leukemia cell line MV4-11 was lower than that of the corresponding parent inhibitors. However, we could also identify degraders such as 15 and 26 that induce potent AURKA degradation and display comparable antiproliferative activities to their parent compound SF1. Compound 15 degrades AURKA with low DC50 value of 2.05 nM, which is 77-fold and 21-fold more selective toward AURKB and TTK and has an EC50 value of 39 nM against cancer MV4-11 cells. Overall, the observations we made with the degrader molecules we developed can further aid in the design and development of optimized TTK or AURK degraders for cancer therapy.

开发基于 2-氨基腺嘌呤的蛋白水解靶向嵌合体 (PROTAC),作为单极纺锤体 1 和极光激酶的新型强效降解剂。
单极纺锤体 1(Mps1,又称 TTK)和极光激酶(AURK)A 和 B 是有丝分裂的关键调节因子,与多种癌症的进展有关。在此,我们报告了一系列针对 TTK 和 AURK 的 PROTACs(蛋白分解靶向嵌合体)的设计、合成和生物学评价。我们以四种不同的2-氨基腺嘌呤配体为基础合成了各种降解剂分子,并招募脑龙或VHL作为E3连接酶。我们的研究表明,连接体的性质和配体的修饰对靶标特异性和降解效果有显著影响。值得注意的是,化合物 19 是最有效的降解剂之一,它表现出蛋白酶体介导的对 TTK 的强效降解,与结构相似的抑制剂对照物 23 相比,D max 为 66.5%,DC50 值(6 小时)为 17.7 nM。大多数合成嵌合体对急性髓性白血病细胞株 MV4-11 的细胞毒性低于相应的母体抑制剂。不过,我们也发现了 15 和 26 等降解剂,它们能诱导 AURKA 强效降解,并显示出与其母体化合物 SF1 相当的抗增殖活性。化合物 15 降解 AURKA 的 DC50 值低至 2.05 nM,对 AURKB 和 TTK 的选择性分别提高了 77 倍和 21 倍,对 MV4-11 癌细胞的 EC50 值为 39 nM。总之,我们对所开发的降解剂分子的观察结果可以进一步帮助设计和开发用于癌症治疗的优化 TTK 或 AURK 降解剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Pharmacology and Translational Science
ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)
CiteScore
10.00
自引率
3.30%
发文量
133
期刊介绍: ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信